NEUPATH HEALTH REPORTS SECOND QUARTER 2025 RESULTS
Menu

Back to Press Releases

NEUPATH HEALTH REPORTS SECOND QUARTER 2025 RESULTS

  • Record second quarter total revenue of $23.6 million, up 25% year-over-year
  • Positive cash flows, with Adjusted EBITDA(1) of $2.2 million, up 69% year-over-year, and our 26th consecutive quarter of positive Adjusted EBITDA
  • Investor webinar scheduled for Thursday, August 21, 2025 at 10:00 AM ET / 7:00 AM PT

TORONTO, ONTARIO, August 14, 2025 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and six months ended June 30, 2025 and information regarding the Company’s investor webinar on Thursday, August 21, 2025. All figures are in Canadian dollars, unless otherwise noted.

“Our core business continues to perform well, supported by improved capacity utilization, strong early demand for Arthrosamid®, and the continued focus by the entire NeuPath team on the patient journey and outcomes,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “Adjusting for the benefit of a one-time retroactive payment, we delivered strong growth and improved cash flows that reflect the work of our team to mitigate cost pressures and optimize our clinic footprint. We expect further investments in the second half of the year to enhance our clinic network, and with the addition of Stephen Lemieux as President, we are accelerating our focus on strategic opportunities. We believe we are well-positioned for continued growth in the second half of 2025 and beyond.”

Financial and Operational Highlights

  • Record total revenue of $23.6 million and $43.0 million for the three and six months ended June 30, 2025, up 25% and 18% year-over-year;
  • Adjusted EBITDA was $2.2 million and $3.5 million for the three and six months ended June 30, 2025, up 69% and 61% year-over-year;
  • For the six months ended June 30, 2025, capacity utilization improved to 79%, up from 75% for the six months ended June 30, 2024;
  • As at June 30, 2025, the Company had $3.8 million in cash and cash equivalents and interest-bearing long-term debt of $6.5 million; and
  • Following the launch of Arthrosamid (2.5% iPAAG) in March, there was substantial uptake in Q2, with continued patient interest in this novel procedure.
  • Non-International Financial Reporting Standard (“IFRS”) and Other Financial Measures defined by the Company below.

View entire press release – PDF

Related Articles